FDA MedWatch - HVAD Pump Implant Kits by Medtronic: Class I Recall

Due to Delayed or Failed Restart After the Pump is Stopped

MedWatch - The FDA Safety Information and Adverse Event Reporting Program TOPIC: HVAD Pump Implant Kits by Medtronic: Class I Recall - Due to Delayed or Failed Restart After the Pump is Stopped AUDIENCE: Patient, Risk Manager, Cardiology  ISSUE: Medtronic is recalling the HeartWare Ventricular Assist Device (HVAD) Pump Implant Kit because the device may fail to initially start, restart, or have a delay in restarting after the pump was stopped. These delays or failures to start or restart have occurred during preimplant testing, during the implant, or in a variety of post-implant situations. If the device has delays or fails to start or restart, this could cause serious patient harm including a heart attack, worsening heart failure, the need for additional procedures and hospitalizations, or death.   There have been 29 complaints about this device issue, which include 19 serious injuries and 8 cases of patients who had a life-threatening event but recovered without long term effects. Two deaths have been reported. For more information about this recall, click on the red button "Read Recall" below. BACKGROUND: The HVAD Pump Implant Kit is part of the HeartWare HVAD System, which is used to help the heart continue to pump blood to the rest of the body. The HVAD system is used as a bridge to cardiac transplants in patients who are at risk of death from end-stage left ventricular heart failure, for heart tissue recovery, or as destination therapy in patients where new transplants are not planned. RECOMMENDATION: On December 18, 2020, Medtronic sent an Urgent Medical Device Communication Letter to all affected customers and on December 23, 2020, Medtronic sent an Urgent Medical Device Communication Letter to all accounts who have previously purchased a Medtronic HVAD Pump. The notice instructed customers to: Advise health care providers and staff the following points from the current Instructions for Use to avoid unnecessary pump stops: Do not disconnect the driveline from the controller. Do not disconnect both power sources (batteries and AC or DC adapter) from the controller at the same time; one external power source should always remain connected to the controller. Do not exchange the controller unless explicitly directed by a High Priority alarm condition or by a Ventricular Assist Device (VAD) team member. Reinforce the proper response to a [Controller Fault] alarm and [Electrical Fault] alarm. These are Medium Priority alarms unrelated to an immediate pump stop. These alarms will result in the word [Call] in the Controller Display, notifying the patient to call their clinician. Reinforce making good connections of power sources and the data cable in the controller ports. Inform patients implanted with one of these identified pumps to contact their VAD coordinator prior to any controller exchange, and to coordinate performing an exchange of controllers in a clinical setting. Decide if a controller exchange is deemed necessary for patients implanted with one of these identified pumps and consider the following: Controller exchanges should be performed under clinician supervision in a controlled environment with immediate ability to put the patient on hemodynamic support. Failure to restart can be fatal. Upon a pump stop, a High Priority [VAD Stopped] alarm will result in the words [Change Controller] or [Connect Driveline] in the Controller Display. Once power and driveline connections are reestablished, if the pump does not restart: Consider power cycling of the current controller or consider a controller exchange. This will allow the restart algorithm to reset and start over. The controller automatically attempts to restart the pump a maximum of 30 times; the [VAD Stopped] alarm begins after five (5) attempts. If the pump still does not restart, proceed with temporary hemodynamic support and pump exchange. Schedule a controller exchange prior to the internal controller battery reaching end of life and triggering a [Controller Fault] alarm if a patient's controller is beyond two (2) years of service. Review serial numbers in the letter and confirm if patients are still on support. Share the letter with all those who need to be aware within organizations or to any organization where potentially affected patients have been transferred. Health professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: Complete and submit the report online. Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on form, or submit by fax to 1-800-FDA-0178.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA